MX2009007889A - Derivados de 3-cinnolincarboxamida y su uso para el tratamiento del cancer. - Google Patents

Derivados de 3-cinnolincarboxamida y su uso para el tratamiento del cancer.

Info

Publication number
MX2009007889A
MX2009007889A MX2009007889A MX2009007889A MX2009007889A MX 2009007889 A MX2009007889 A MX 2009007889A MX 2009007889 A MX2009007889 A MX 2009007889A MX 2009007889 A MX2009007889 A MX 2009007889A MX 2009007889 A MX2009007889 A MX 2009007889A
Authority
MX
Mexico
Prior art keywords
cinnolinecarboxamide
derivatives
treating cancer
manufacture
formula
Prior art date
Application number
MX2009007889A
Other languages
English (en)
Inventor
Xiaolan Zheng
David Scott
Leslie Dakin
Claude Afona Ogoe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39310013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009007889(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2009007889A publication Critical patent/MX2009007889A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos químicos de fórmula (i): (ver fórmula (i)) o sales farmacéuticamente aceptables de lo mismo que poseen actividad inhibitoria de la cinasa de la CFS-1R y son por consiguiente útiles para su actividad anticancerígena y así en métodos de tratamiento del cuerpo humano o animal. La invención también se relaciona con los procesos para la fabricación de tales compuestos químicos, con las composiciones farmacéuticas que las contienen y con su uso en la fabricación de medicamentos del uso en la producción de un efecto anticancerígeno en un animal de sangre caliente tal como el hombre.
MX2009007889A 2007-01-25 2008-01-24 Derivados de 3-cinnolincarboxamida y su uso para el tratamiento del cancer. MX2009007889A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88658507P 2007-01-25 2007-01-25
US95157607P 2007-07-24 2007-07-24
PCT/GB2008/000256 WO2008090353A1 (en) 2007-01-25 2008-01-24 3 - cinnolinecarboxamide derivatives and their use for treating cancer

Publications (1)

Publication Number Publication Date
MX2009007889A true MX2009007889A (es) 2009-07-31

Family

ID=39310013

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007889A MX2009007889A (es) 2007-01-25 2008-01-24 Derivados de 3-cinnolincarboxamida y su uso para el tratamiento del cancer.

Country Status (18)

Country Link
US (2) US7723337B2 (es)
EP (1) EP2118072A1 (es)
JP (1) JP2010500988A (es)
KR (1) KR20090111337A (es)
AR (1) AR065042A1 (es)
AU (1) AU2008208751A1 (es)
BR (1) BRPI0808005A2 (es)
CA (1) CA2675621A1 (es)
CL (1) CL2008000191A1 (es)
CO (1) CO6190614A2 (es)
EC (1) ECSP099539A (es)
IL (1) IL199911A0 (es)
MX (1) MX2009007889A (es)
PE (1) PE20081693A1 (es)
RU (1) RU2009131834A (es)
TW (1) TW200843775A (es)
UY (1) UY30880A1 (es)
WO (1) WO2008090353A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
US20110190272A1 (en) * 2008-05-07 2011-08-04 Astrazeneca Ab Chemical compounds
EP2726465A1 (en) * 2011-05-23 2014-05-07 Elan Pharmaceuticals Inc. Inhibitors of lrrk2 kinase activity
WO2013148603A1 (en) * 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
CN108884084A (zh) * 2016-03-21 2018-11-23 阿斯利康(瑞典)有限公司 噌啉-4-胺化合物及其在治疗癌症中的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621425D0 (en) * 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
DK273689A (da) * 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
DK0480052T3 (da) * 1990-03-28 1998-05-11 Otsuka Pharma Co Ltd Quinolinderivat, antiulcus-lægemiddel indeholdende derivatet og fremstilling af derivatet
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
SE0101675D0 (sv) * 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
GB0322726D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
AR053992A1 (es) 2004-12-22 2007-05-30 Astrazeneca Ab Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
WO2006124996A2 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
WO2007119046A1 (en) 2006-04-14 2007-10-25 Astrazeneca Ab 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors
TW200829555A (en) 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
AR065042A1 (es) 2009-05-13
WO2008090353A1 (en) 2008-07-31
AU2008208751A1 (en) 2008-07-31
US20110098283A1 (en) 2011-04-28
PE20081693A1 (es) 2009-01-18
EP2118072A1 (en) 2009-11-18
KR20090111337A (ko) 2009-10-26
CO6190614A2 (es) 2010-08-19
UY30880A1 (es) 2008-09-02
CA2675621A1 (en) 2008-07-31
US7723337B2 (en) 2010-05-25
TW200843775A (en) 2008-11-16
RU2009131834A (ru) 2011-02-27
JP2010500988A (ja) 2010-01-14
IL199911A0 (en) 2010-04-15
BRPI0808005A2 (pt) 2013-07-30
CL2008000191A1 (es) 2008-08-22
US20090012084A1 (en) 2009-01-08
ECSP099539A (es) 2009-08-28

Similar Documents

Publication Publication Date Title
MX2009004908A (es) Compuestos quimicos.
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
WO2006067445A3 (en) Csf-1r kinase inhibitors
WO2007071963A3 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
WO2007113558A3 (en) Quinazolinone derivatives having b-raf inhibitory activity
MX2007008924A (es) Compuestos quimicos.
TW200634003A (en) Chemical compounds
TW200616974A (en) Chemical compounds
TW200736234A (en) Chemical compounds
TW200621259A (en) Chemical compounds
TW200621730A (en) Chemical compounds
MX2010002353A (es) Amidas heterociclicas utiles para tratamiento de cancer y psoriais.
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
HK1157337A1 (es)
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
EA025086B9 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
MX2014004479A (es) Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades.
WO2008068507A3 (en) 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
MX2012001838A (es) Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal